Acute myeloid leukemia: current progress and future directions

Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML) is occurring rapidly. Since 2017, nine agents have been approved for various indications in AML. These included several targeted therapies like venetoclax, FLT3 inhibitors, IDH inhibitors, and others. The manage...

Descripción completa

Detalles Bibliográficos
Autores principales: Kantarjian, Hagop, Kadia, Tapan, DiNardo, Courtney, Daver, Naval, Borthakur, Gautam, Jabbour, Elias, Garcia-Manero, Guillermo, Konopleva, Marina, Ravandi, Farhad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7900255/
https://www.ncbi.nlm.nih.gov/pubmed/33619261
http://dx.doi.org/10.1038/s41408-021-00425-3
_version_ 1783654187594153984
author Kantarjian, Hagop
Kadia, Tapan
DiNardo, Courtney
Daver, Naval
Borthakur, Gautam
Jabbour, Elias
Garcia-Manero, Guillermo
Konopleva, Marina
Ravandi, Farhad
author_facet Kantarjian, Hagop
Kadia, Tapan
DiNardo, Courtney
Daver, Naval
Borthakur, Gautam
Jabbour, Elias
Garcia-Manero, Guillermo
Konopleva, Marina
Ravandi, Farhad
author_sort Kantarjian, Hagop
collection PubMed
description Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML) is occurring rapidly. Since 2017, nine agents have been approved for various indications in AML. These included several targeted therapies like venetoclax, FLT3 inhibitors, IDH inhibitors, and others. The management of AML is complicated, highlighting the need for expertise in order to deliver optimal therapy and achieve optimal outcomes. The multiple subentities in AML require very different therapies. In this review, we summarize the important pathophysiologies driving AML, review current therapies in standard practice, and address present and future research directions.
format Online
Article
Text
id pubmed-7900255
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-79002552021-03-05 Acute myeloid leukemia: current progress and future directions Kantarjian, Hagop Kadia, Tapan DiNardo, Courtney Daver, Naval Borthakur, Gautam Jabbour, Elias Garcia-Manero, Guillermo Konopleva, Marina Ravandi, Farhad Blood Cancer J Review Article Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML) is occurring rapidly. Since 2017, nine agents have been approved for various indications in AML. These included several targeted therapies like venetoclax, FLT3 inhibitors, IDH inhibitors, and others. The management of AML is complicated, highlighting the need for expertise in order to deliver optimal therapy and achieve optimal outcomes. The multiple subentities in AML require very different therapies. In this review, we summarize the important pathophysiologies driving AML, review current therapies in standard practice, and address present and future research directions. Nature Publishing Group UK 2021-02-22 /pmc/articles/PMC7900255/ /pubmed/33619261 http://dx.doi.org/10.1038/s41408-021-00425-3 Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Review Article
Kantarjian, Hagop
Kadia, Tapan
DiNardo, Courtney
Daver, Naval
Borthakur, Gautam
Jabbour, Elias
Garcia-Manero, Guillermo
Konopleva, Marina
Ravandi, Farhad
Acute myeloid leukemia: current progress and future directions
title Acute myeloid leukemia: current progress and future directions
title_full Acute myeloid leukemia: current progress and future directions
title_fullStr Acute myeloid leukemia: current progress and future directions
title_full_unstemmed Acute myeloid leukemia: current progress and future directions
title_short Acute myeloid leukemia: current progress and future directions
title_sort acute myeloid leukemia: current progress and future directions
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7900255/
https://www.ncbi.nlm.nih.gov/pubmed/33619261
http://dx.doi.org/10.1038/s41408-021-00425-3
work_keys_str_mv AT kantarjianhagop acutemyeloidleukemiacurrentprogressandfuturedirections
AT kadiatapan acutemyeloidleukemiacurrentprogressandfuturedirections
AT dinardocourtney acutemyeloidleukemiacurrentprogressandfuturedirections
AT davernaval acutemyeloidleukemiacurrentprogressandfuturedirections
AT borthakurgautam acutemyeloidleukemiacurrentprogressandfuturedirections
AT jabbourelias acutemyeloidleukemiacurrentprogressandfuturedirections
AT garciamaneroguillermo acutemyeloidleukemiacurrentprogressandfuturedirections
AT konoplevamarina acutemyeloidleukemiacurrentprogressandfuturedirections
AT ravandifarhad acutemyeloidleukemiacurrentprogressandfuturedirections

Ejemplares similares